Novartis has announced that it is exercising its option to license the rights to develop and commercialise Akcea's TQJ230.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.